NSNilanchali Singh

Nilanchali Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nilanchali Singh has a total of 155 co-authors. Here are the top co-authors by number of shared publications:

  • Reva Tripathi

    Director Professor & Head of Department, Department of Obstetrics and Gynaecology, Maulana Azad Medical College, India

    8 shared publications
  • Prafull Ghatage

    Department of Gynecologic oncology, Tom Baker Cancer Center, Cumming School of Medicine, University of Calgary, Calgary, Canada

    7 shared publications
  • Jyoti Meena

    Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences

    5 shared publications
  • Seema Singhal

    Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences

    5 shared publications
  • Atul Batra

    Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India

    4 shared publications
  • Yedla Manikya Mala

    Department of Obstetrics and Gynaecology, Maulana Azad Medical College and Associated Lok Nayak Hospital, Bahadur Shah Zafar Marg, Delhi Gate, New Delhi 110002, India

    4 shared publications

Latest Publications

  • Open Access

    Association of viral load values with cervical lesion severity and exploratory genotype analysis in HPV-positive Indian women

    by Nilanchali Singh, Zakiya Zakiya, Seema Singhal, Jyoti Meena, Rajesh Kumari, Anju Singh, Iman Dandapath, Anjli Gaur, Pranay Tanwar, Sandeep Mathur, et al.

    Background: Hybrid Capture 2 (HC2) provides a semi-quantitative estimate of high-risk human papillomavirus (HPV) burden as relative light units/cutoff (RLU/CO), and HPV genotyping may add value to triage assessment. We evaluated the association of RLU/CO with cervical lesion severity and explored whether genotype information improves diagnostic performance in HPV-positive Indian women. Methods: This cross-sectional study was conducted in two sequential phases. In the initial phase, 217 consecutive HPV-positive women underwent HC2 HPV DNA testing, colposcopy-guided biopsy, and histopathological assessment. In a subsequent phase, an additional group of 111 HPV-positive women underwent the same clinical and histopathological assessment and also provided specimens for HPV genotyping. The genotype-enriched group was analysed separately for genotype distribution, co-infection patterns, and exploratory genotype-integrated prediction models. Age, Histopathology, and viral load (HC2 RLU/CO) were analysed in the full cohort. The genotyped subset was additionally evaluated for HPV genotype distribution and genotype-integrated ROC models. Descriptive statistics, Kruskal–Wallis testing with Holm-adjusted Dunn's post-hoc comparisons, and ROC analyses with 95% confidence intervals and paired DeLong comparisons were performed. Results: RLU/CO values differed across study-specific histopathological severity categories, with higher median values in LSIL, HSIL, and invasive cervical cancer than in normal histology and chronic cervicitis. In the cohort of 328 women, RLU/CO discriminated HSIL or invasive cervical cancer (severity score ≥3) with an AUC of 0.798 (95% CI, 0.726–0.868). A study-derived Youden-index cutoff of 12.08 RLU/CO yielded a sensitivity of 81.1% (95% CI, 69.5%–90.9%) and specificity of 73.1% (95% CI, 68.0%–78.0%). Among 111 genotyped participants, HPV16 was the most frequently detected genotype, and multiple-genotype infections occurred in 64 participants (57.7%). In the genotyped subgroup, comparative ROC analysis for HSIL or invasive cervical cancer showed AUCs of 0.659 for RLU/CO alone, 0.608 for RLU/CO plus HPV16/18, and 0.461 for RLU/CO plus other high-risk HPV. Neither genotype-integrated model improved discrimination compared with RLU/CO alone; these exploratory estimates require validation in larger independent cohorts. Conclusion: HC2 RLU/CO showed potential for identifying HSIL or invasive cervical cancer. The study-derived cutoff requires validation in independent populations. Genotype-integrated models showed variable performance in the small subgroup. The HPV16/18 model was comparable to RLU/CO alone, but findings were exploratory. Larger prospective studies are needed before clinical implementation.

  • Clinical Performance and User-Informed Refinement of an Indigenous HPV Self-Collection Device for Cervical Cancer Screening in Resource-Constrained Settings

    by Seema Singhal, Pranay Tanwar, Aarthi S. Jayraj, Shahin Naz. Jamali, Kirti Garg, Alankrita Sharma, Sandeep Mathur, Nilanchali Singh, Neena Malhotra, Neerja Bhatla

    Background: HPV self-sampling has improved screening participation but remains constrained by cost and lack of optimised collection devices in resource-constrained settings. This study reports the iterative development of an indigenous self-collection device across successive prototypes. Methods: In this prospective study, women ≥ 30 years were recruited from community and higher-risk clinical cohorts including women living with HIV and colposcopy referrals. Each participant used one of three CERVICHECK™ prototypes (P1–P3) for vaginal self-sampling, followed by physician-collected cervical sampling. Self-collected samples were tested using an indigenous PCR-based HPV assay and physician-collected samples using Cobas 6800. Clinical performance was assessed against histologically confirmed CIN2+ as the primary endpoint. Results: Of 756 enrolled women, 743 paired samples were evaluable; invalidity rate was 1.7%. Iterative device refinement was associated with stepwise improvements in analytical agreement with reference standard (Cohen’s κ: P1:0.49; P2:0.47; P3:0.67). Clinical sensitivity for CIN2+ detection using self-collected samples increased from 40.0% (95%CI 5.3–85.3) with P1 to 75.0% (95%CI 34.9–96.8) with P2 and 93.6% (95%CI 78.6–99.2) with P3. For P3, clinical sensitivity and specificity of self-collected samples was 93.6% (95%CI 78.6–99.2) for CIN2+ and 67.4% (95%CI 58.6–75.4) for ≤CIN1 lesions, yielding a relative clinical sensitivity of 1.0. Reported concerns declined across successive prototypes (P1:47.6%, P2:25.5%, P3:13.4%). Conclusions: Iterative, user-informed refinement of indigenous HPV self-collection device achieved clinically meaningful performance comparable to standard sampling for CIN2+ detection. Impact: Optimised affordable indigenous self-collection solutions may offer scalable and equitable options for implementing HPV-based cervical cancer screening in resource-constrained settings.

  • Open Access

    Soluble E-selectin and QRISK3-based Cardiovascular Risk Assessment in Women with Polycystic Ovary Syndrome: A Prospective Case–control Study from India

    by Nilanchali Singh, Iman Dandapath, Akanksha Gupta, Surabhi Gupta, Rosemary Jha, Deepti Siddharthan, Ashwani Kumar Mishra, D. Kathiravan, Neeta Singh, Zakiya Zakiya

    A BSTRACT: Background: Polycystic ovary syndrome (PCOS) is associated with metabolic abnormalities and increased long-term cardiovascular risk. Endothelial dysfunction is considered an early event in atherogenesis, and soluble E-selectin has been proposed as a marker of endothelial activation. However, its role in cardiovascular risk assessment in PCOS remains uncertain. Aim: The study aimed to compare circulating soluble E-selectin levels between women with PCOS and healthy controls and evaluate their association with metabolic parameters and QRISK3-based cardiovascular risk scores. Settings and Design: Prospective hospital-based case–control study. Materials and Methods: Two hundred women with PCOS diagnosed according to the Rotterdam criteria and 50 age-matched healthy controls aged 18–40 years were enrolled. Clinical assessment, anthropometry, fasting blood glucose, HbA1c, lipid profile, C-reactive protein and soluble E-selectin levels were evaluated. Estimated 10-year cardiovascular risk was calculated using the QRISK3 algorithm. Statistical Analysis Used: Group comparisons, correlation analyses and multivariable linear regression were performed. Results: Mean soluble E-selectin levels were comparable between women with PCOS and controls (0.61 ± 0.33 vs. 0.61 ± 0.29 ng/mL, P = 0.935). Within the PCOS group, soluble E-selectin correlated positively with HbA1c ( r = 0.326, P = 0.001) and fasting blood glucose ( r = 0.271, P = 0.001), while no significant associations were observed with anthropometric measures, lipid parameters, blood pressure or QRISK3 scores. In multivariable analysis, fasting blood glucose remained independently associated with soluble E-selectin. Conclusion: Soluble E-selectin levels did not differ between women with PCOS and controls and showed limited associations with cardiovascular risk factors. These findings do not support a major role for soluble E-selectin in cardiovascular risk assessment among young women with PCOS.

  • Open Access

    Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors: A Cross-Sectional Study

    by Nilanchali Singh, Shalini Singh, Rizwana Quraishi, Dn Sharma, Zakiya Zakiya, Seema Singhal, Jyoti Meena, Shivangi Mangal, Garg Himakshi, Rajesh Kumari, et al.

    Introduction: Female sexual dysfunction (FSD) in any gynaecological cancer survivor is one aspect of female functioning that is neglected in survivorship care. Therefore, their actual prevalence is far from known to the treating physician. This study aimed to evaluate the prevalence of sexual dysfunction in gynaecological cancer survivors, determine its risk factors, and correlate sexual dysfunction with serum neurotropic factors. Methods: This was a cross-sectional, observational study among 200 gynaecological cancer survivors who are sexually active, conducted in the gynaecological cancer clinic at a tertiary care centre. Sexual function was assessed using the Hindi-validated Female Sexual Function Index (FSFI), and serum brain-derived neurotrophic factor (BDNF), substance P, and neuropeptide Y (NPY) were measured by ELISA. The correlation between these biomarkers, with domains and subdomains of the female sexual function index, was explored. Results: In this cohort of 200 gynaecological cancer survivors, 189 (94.5%) women had FSD (FSFI <26.55). Age was the only independent clinical predictor of FSD in multivariable analysis (p = 0.02), while cancer site, stage, treatment modality, and menopausal status were not significant in this cohort. Overall biomarker levels did not differ between women with and without FSD. However, subdomain analysis showed high dysfunction rates in lubrication, orgasm, pain, and arousal, with significant biomarker differences for substance P and NPY in several dysfunctional subdomains. Conclusions: FSD was highly prevalent in gynaecological cancer survivors. While overall biomarker differences were not significant, subdomain-specific associations suggest that substance P and NPY may have a role in domain-level sexual dysfunction and merit further study.

  • Endometrial actinomycosis: a treatable cause of postmenopausal bleeding

    by Akanksha Gupta, Nilanchali Singh, Riya Bagdi, Ridhi Sood, Neena Malhotra

    Postmenopausal bleeding (PMB) raises significant concern in women, as it may signal early uterine malignancy. Consequently, all episodes of PMB require thorough investigation. Approximately 60–80% of cases are linked to atrophic endometrium, with about 10% each attributable to endometrial hyperplasia and carcinoma. However, one case involved a woman with PMB, where no definitive cause was identified beyond a forgotten intrauterine contraceptive device. Further evaluation revealed a rare uterine infection as the underlying cause of the PMB.

  • Open Access

    Role of Training Paramedical Staff for Cervical Cancer Screening via Human Papillomavirus Self-Sampling in Remote Mountainous Regions: A Pilot Feasibility Study

    by Nilanchali Singh, Vikas Raj Jalagam, Sushmitha Somagattu, Sadaf Kunwar, Pranay Tanwar

    Background Cervical cancer is the second most common cancer among women in India and a leading cause of cancerrelated deaths in low-and middle-income countries. Despite the availability of effective screening methods, coverage remains low in India due to limited awareness, logistical barriers, and poor access, especially in remote regions. The World Health Organization recommends human papillomavirus (HPV) DNA testing as the preferred screening method, and self-sampling has emerged as a promising strategy to increase participation. This study aimed to evaluate the feasibility and acceptability of HPV self-sampling for cervical cancer screening through trained paramedical staff in a community-based pilot study conducted in a remote mountainous region of Ladakh, India. Methodology This was a pilot, observational feasibility study conducted during a community-based health camp in Kargil, Ladakh. Paramedical staff (auxiliary nurse midwives) were trained through demonstrations and videos to counsel women on HPV self-sampling. Women were educated and offered self-sampling kits (Digene HC2 High-Risk HPV DNA, Qiagen). Samples were collected on-site and transported to New Delhi for testing. Reports were shared via mobile phone and followed up by local gynecologists. Results Of the 50 women counseled, 47 (94%) consented to HPV self-sampling. One tested positive (2.1%) for highrisk HPV and was referred for further evaluation. The high acceptability indicates the feasibility of this approach in remote areas. Conclusions This pilot study demonstrates that training paramedical staff for HPV self-sampling facilitated by trained paramedical staff appears to be a feasible and acceptable approach for cervical cancer screening in remote settings. This approach can bridge screening gaps and support national efforts toward cervical cancer elimination.

  • Open Access

    Clinico-pathological Features of Placental Tumors

    by Baishali Roy, Nilanchali Singh

    Placental tumors are a result of abnormal proliferation of placental tissues. This includes both gestational trophoblastic diseases (GTD) and nontrophoblastic tumours. Gestational trophoblastic neoplasia (GTN) includes both premalignant (hydatidiform mole) and malignant tumours (invasive moles, choriocarcinoma, placental site trophoblastic tumor, epithelioid trophoblastic tumor and atypical placental site nodule). GTD incidence is high in Asia and Latin America. Patients usually present with abnormal uterine bleeding. Patients with mutations in NLRP7 and KHDC3 L genes linked to recurrent molar pregnancies and human leukocyte antigen (HLA) haplotypes (HLA-DRB1, HLA-DQB1) associated with increased susceptibility. Early detection of molar pregnancy via ultrasound and serial beta human chorionic gonadotropin monitoring can help reach a diagnosis. Federation of Gynecology and Obstetrics (FIGO) criteria have to be met in order to make a diagnosis of GTN. FIGO scoring (low risk 13) and staging are mandatory before planning further management.

  • Open Access

    Evaluating The Feasibility and Acceptability of Cervical Cancer Screening in an Urban Slum Community by HPV Self-Sampling With the Aid of Telecounselling: Lessons Learnt

    by Nilanchali Singh, Shivangi Mangal, Pranay Tanwar, Seema Singhal, Akanksha Yadav, Sandeep Mathur

    HPV testing is the most sensitive method of secondary cervical cancer prevention and the preferred method recommended by the World Health Organization. To increase cervical cancer screening, self-sampling has been introduced, which has shown significant results in improving access and simplifying screening for large and remote populations in low- and middle-income countries. This study aims to evaluate the feasibility and acceptability of HPV self-sampling in an urban slum community using tele-counselling, which is a niche population for HPV positivity and HPV-related diseases. This study is a community-based, prospective, single-arm design. Women were counselled telephonically about the methods of self-sampling, and HPV self-sampling kits were couriered to them. The collected kits were returned via courier and tested at the study site. In the case of a positive test result, the individual was linked to treatment at the study center. Test positives were offered either a 'see and treat' approach or colposcopy triage. In the community, 982 women were enrolled in the study, but only 600 (61%) women consented to screening by HPV self-sampling. Ninety-six (15.6%) out of 600 women tested positive for Hr-HPV. Age, educational status, locality, occupation, menopausal status, and smoking status were similar in both screen-negative and screen-positive groups. Among the 600 women, 570 (95%) found it easy to take a self-sample, and 588 (98%) were satisfied with the overall experience. CIN I was found in 6 (6.4%), and CIN II was found in 4 (4.3%) cases. LEEP was performed in patients diagnosed with CIN II. HPV self-sampling is an acceptable method of cervical cancer screening, with an acceptance rate of 61% among urban slum women. It demonstrates that HPV self-sampling is feasible when supported by tele-counselling.


  • Open Access

    Telemedicine: The New Vanguard in Gynecological Care

    by Nilanchali Singh, Saumya Kulshrestha, Nimisha Agrawal, Deepali Garg, Rinchen Zangmo, Sushmitha Somagattu, Akanksha Yadav, K K. Roy, Saumya Kulshrestha Sr.

    Background and objectives: The COVID-19 pandemic necessitated a shift in healthcare delivery, with both patients and physicians seeking alternatives to minimize hospital visits. Telemedicine has emerged as a viable solution, offering comparable health outcomes to conventional in-person consultations while improving patient satisfaction. This study aims to present our experience in establishing a teleconsultation service for antenatal patients, evaluating its impact on maternal and fetal outcomes, as well as patient satisfaction. Methodology: A dedicated teleconsultation unit was initiated in April 2020 to manage antenatal care remotely. Patients received virtual consultations, with in-person appointments scheduled only when clinically necessary. Data were collected on teleconsultations, maternal and fetal outcomes, and patient satisfaction. Additionally, feedback from both patients and healthcare providers was recorded to assess the effectiveness of the service. Results: Over one year, teleconsultation services were provided to 2,340 patients, including 1,550 antenatal cases and 790 with gynecological concerns. Among antenatal patients, 1,390 successfully completed teleconsultations, with 109 receiving teleconsultation services without prior appointments. Each antenatal patient, on average, had three virtual consultations and two in-person visits. A total of 76% of antenatal patients were scheduled for follow-up teleconsultations. Furthermore, 18% required in-person evaluations, 3% were directly advised of admission following teleconsultation, and 2% were referred for fetal medicine interventions, including chorionic villus sampling, amniocentesis, or advanced ultrasound assessments. The average duration of a teleconsultation was 5 minutes and 15 seconds, and 90% of patients reported satisfaction with the service. Conclusion: Teleconsultation proved to be an effective strategy for reducing the need for physical visits while maintaining favorable maternal and fetal outcomes. High patient satisfaction rates further highlight its feasibility as a sustainable model for antenatal care.


  • Open Access

    Vaginal Neoplasm in a Breast Cancer Survivor: A Case Report

    by Baishali Roy, Ruchi Rathore, Seema Singhal, Sholanki Halder, Nilanchali Singh

    According to GLOBOCAN 2022 data, Carcinoma breast is the second most common malignancy worldwide after lung and ranks 4th in mortality worldwide. Breast cancer can metastasize to various organs. The incidence of vaginal metastasis in carcinoma breast is 1-2%. Here we present a patient with post menopausal bleeding with vaginal mass. She had a history of Triple negative carcinoma left breast 3 years back, treated by Modified Radical Mastectomy followed by chemo radiotherapy. Vaginal biopsy was suggestive of a metastatic carcinoma breast. MRI and PET CT showed isolated vaginal growth. Due to poor performance status and multiple medical comorbidities, decision was taken to treat her with single agent Paclitaxel 3weekly until disease progression. This case report points out the necessity for thorough gynaecological examination in a cancer survivor, either via clinical examination, routine PAP smear or imaging.